Search
Find a recruiting study
7,120 recruiting studies with US sites, from the official ClinicalTrials.gov registry (refreshed Oct 26, 2026). No sign-up needed.
Most recently updated studies · page 68 of 297
- RecruitingPhase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Eli Lilly and Company
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 12+
- Recruiting
The HYALEX Pivotal Study
Hyalex Orthopaedics, Inc.
- Location
- La Mesa, CA + 3 other US sites
- Eligibility basics
- Ages 22–70
- RecruitingPhase 1/Phase 2
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Ascidian Therapeutics, Inc
- Location
- Gainesville, FL + 8 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company
- Location
- Morehead City, NC
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Phoenix, AZ + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Dothan, AL + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Dothan, AL + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
- Location
- Wilmington, DE + 7 other US sites
- Eligibility basics
- Ages 6–17
- Recruiting
A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint
Eli Lilly and Company
- Location
- New York, NY
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Eli Lilly and Company
- Location
- Rockville, MD + 1 other US site
- Eligibility basics
- Ages 18–75
- Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
Avisi Technologies Inc.
- Location
- Glendale, AZ + 9 other US sites
- Eligibility basics
- Ages 45+
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Birmingham, AL + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
AstraZeneca
- Location
- Sacramento, CA + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Eli Lilly and Company
- Location
- Orange, CA + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular…
Guerbet
- Location
- Evanston, IL
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- Little Rock, AR + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
Eli Lilly and Company
- Location
- Phoenix, AZ + 35 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
Dompé Farmaceutici S.p.A
- Location
- Huntington Beach, CA + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
Alkermes, Inc.
- Location
- Brandon, FL + 14 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S
- Location
- Gilbert, AZ + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Birmingham, AL + 20 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Kymera Therapeutics, Inc.
- Location
- Miami, FL + 2 other US sites
- Eligibility basics
- Ages 18+
Data source: deploy-time snapshot of the ClinicalTrials.gov API. How we list studies